Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-3.27 Insider Own2.30% Shs Outstand346.14M Perf Week3.24%
Market Cap4.97B Forward P/E4.01 EPS next Y3.58 Insider Trans-65.40% Shs Float343.62M Perf Month-18.19%
Income-1143.00M PEG- EPS next Q0.92 Inst Own66.80% Short Float8.42% Perf Quarter7.81%
Sales9.22B P/S0.54 EPS this Y-714.90% Inst Trans20.32% Short Ratio1.60 Perf Half Y-12.23%
Book/sh11.23 P/B1.28 EPS next Y-3.45% ROA-2.60% Target Price- Perf Year-54.11%
Cash/sh3.51 P/C4.09 EPS next 5Y-9.43% ROE-30.20% 52W Range8.31 - 32.74 Perf YTD-1.17%
Dividend- P/FCF2.28 EPS past 5Y61.43% ROI-1.60% 52W High-56.10% Beta-0.31
Dividend %- Quick Ratio1.10 Sales past 5Y31.90% Gross Margin72.20% 52W Low72.98% ATR0.63
Employees21500 Current Ratio1.30 Sales Q/Q-7.70% Oper. Margin-4.20% RSI (14)37.47 Volatility3.53% 4.39%
OptionableYes Debt/Eq7.28 EPS Q/Q87.60% Profit Margin-12.40% Rel Volume0.40 Prev Close14.35
ShortableYes LT Debt/Eq7.03 EarningsAug 08 BMO Payout- Avg Volume18.13M Price14.38
Recom3.00 SMA20-5.35% SMA50-8.36% SMA2002.40% Volume6,279,628 Change0.18%
Aug-03-17Reiterated RBC Capital Mkts Sector Perform $19 → $21
Jun-16-17Initiated Cantor Fitzgerald Overweight $18
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-21-17 09:34AM  What's The FDA Saying About Valeant's Manufacturing Facility Issues? Benzinga
08:01AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals Intl Inc. and VIVUS Inc. ACCESSWIRE
Aug-18-17 09:53AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Gamble You Can Win InvestorPlace
08:00AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
07:39AM  Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain
Aug-17-17 11:27AM  Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today InvestorPlace
09:38AM  Valeant: Hard to Ignore the Positive Developments?
07:50AM  Valeants Tampa manufacturing plant on track for a better bill of health American City Business Journals
Aug-16-17 07:24PM  Valeant Pharmaceuticals: Cramer's Top Takeaways
07:18PM  Valeant's Papa: 'It's been a challenging 15 months, but w... CNBC Videos
06:41PM  Valeant Pharmaceuticals CEO Joe Papa: 'It's been a challe... CNBC Videos
06:26PM  Valeant Pharmaceuticals CEO: 'It's been a challenging 15 months, but we've made great progress' CNBC
04:49PM  Valeant Pharma works to resolve FDA concerns at Tampa plant MarketWatch
04:15PM  Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility PR Newswire
04:15PM  Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility CNW Group
11:25AM  Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
10:16AM  The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak InvestorPlace
Aug-14-17 11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks
Aug-12-17 08:01AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
Aug-11-17 10:20AM  When the drugmaker raised these heart drugs prices, patients stopped getting them MarketWatch
09:59AM  Valeant: Three Steps to a Recovery?
07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-10-17 07:22PM  Robert Bruce Invests in Valvoline, 2 Pharmaceutical Companies
09:03AM  5 Reasons Valeant's Situation Could Get Worse Motley Fool
Aug-09-17 06:36PM  Valeant and Teva Share Similar Ambitions With Similar Pitfalls -10.04%
06:05PM  Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy PR Newswire
06:05PM  Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy CNW Group
04:38PM  Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10% Motley Fool
04:30PM  Why Priceline Group, Office Depot, and Valeant Pharmaceuticals International Slumped Today Motley Fool
04:15PM  Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today Motley Fool
04:04PM  CANADA STOCKS-TSX ends lower as Valeant, financials drag Reuters
03:23PM  Valeant Isn't Out Of The Woods Yet Benzinga
03:08PM  Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View Zacks
12:02PM  Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to Curb
09:45AM  Wednesdays Vital Data: Bank of America Corp (BAC), SeaWorld Entertainment Inc. (SEAS) and BP plc (ADR) (BP) InvestorPlace
09:41AM  Valeant: A Plausible Path Forward?
09:32AM  Your first trade for Wednesday, August 9 CNBC
09:16AM  Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement Motley Fool
08:20AM  Valeant is on track to reduce about $5 billion of debt. But it has more than $27 billion to go MarketWatch
08:10AM  Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals ACCESSWIRE
07:40AM  Working on a turnaround, Valeant gets a setback from its Bausch & Lomb plant in Tampa American City Business Journals
Aug-08-17 06:03PM  Valeant Rises on Earnings Beat, Progress on Debt Repayment
05:58PM  Valeant reports 2Q loss Associated Press
04:34PM  Valeant Bonds Rise on Early Debt Repayment
03:15PM  [$$] Valeant/Teva: lost summer Financial Times
03:06PM  Valeant Pharmaceuticals: Bears Will Be Bears
02:34PM  Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10% Motley Fool
01:17PM  Valeant Shares Gain on Strength of Xifaxan Bloomberg Video
12:21PM  [$$] Valeant gains breathing room during recovery Financial Times
11:47AM  Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue Motley Fool
11:45AM  Valeant says it will exceed debt repayment target, shares surge Reuters
11:35AM  Valeant: Time, Time, Time is on My Side
11:28AM  Valeant's Guidance Gymnastics Point to a Cut Bloomberg
11:05AM  Is This the Turnaround Valeant Pharma Has Been Waiting For? 24/7 Wall St.
11:00AM  CANADA STOCKS-TSX up on Valeant, Ritchie results; BlackBerry falls on sell rating Reuters
10:32AM  ADP Stock Breakout Just Getting Started Investopedia
10:23AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Scores 2 Vital Victories InvestorPlace
09:45AM  CANADA STOCKS-TSX opens higher; Valeant jumps Reuters
09:40AM  Tuesdays Vital Data: Apple Inc. (AAPL), Alibaba Group Holding Ltd (BABA) and Valeant Pharmaceuticals Intl Inc (VRX) InvestorPlace
09:29AM  Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study
09:10AM  Morning News Call Canadienne - Aout 8 Reuters
08:46AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock? Zacks
08:42AM  Morning Movers: Valeant Soars, Michael Kors Jumps, Avis Budget Tumbles
08:20AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals ACCESSWIRE
07:42AM  UPDATED: Valeant stock surges 7.9% after Q2 loss, 2017 revenue guidance cut MarketWatch
07:33AM  Valeant's Top Drug Is Growing Again, Offsetting Wider Slump Bloomberg
07:14AM  Valeant revenue falls 8 pct Reuters
07:00AM  Valeant Announces Second-Quarter 2017 Results CNW Group
05:10AM  Investor Network: Valeant Pharmaceuticals International Inc to Host Earnings Call ACCESSWIRE
04:22AM  Left Brain CEO: Valeant earnings a 'turnaround story' CNBC Videos
Aug-07-17 04:32PM  PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y Zacks
04:17PM  Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA CNW Group
03:10PM  The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt) Motley Fool
10:04AM  Valeant: Why Teva's Blowup Could Be Good News
09:53AM  How Valeant Pharmaceuticals Intl Inc (VRX) Stock Can Make a Comeback InvestorPlace
09:26AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : VRX-US : August 7, 2017 Capital Cube
Aug-06-17 03:02PM  3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results Motley Fool
10:20AM  Disney, Snap and More of the Top Earnings to Watch This Week 24/7 Wall St.
Aug-05-17 11:52AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
Aug-04-17 01:57PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock: Stupid Is as Stupid Does InvestorPlace
01:40PM  3 Big Stock Charts for Friday: GoPro Inc (GPRO), Valeant Pharmaceuticals Intl Inc (VRX) and Microchip Technology Inc. (MCHP) InvestorPlace
10:49AM  Here's Bill Ackman's Latest Bet After Valeant, Herbalife, Chipotle Setbacks Investor's Business Daily
10:38AM  P&G, Valeant Exemplify Wall Street's 'Overboarded' Problem; Musk Must Raise Funds
08:00AM  Today's Research Reports on Trending Tickers: Dynavax Technologies and Valeant Pharmaceuticals ACCESSWIRE
Aug-03-17 10:51AM  'Boring' Valeant Poised for Q2 Beat -5.91%
10:10AM  Valeant: Why Boring is Better
Aug-02-17 11:41AM  Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Catch a Break? InvestorPlace
09:49AM  Bill Ackmans Pershing Square Capitals Top Sells in 1Q17 Market Realist
09:49AM  Why ADP Stock Rose on Reports of Bill Ackmans Position Market Realist
Aug-01-17 06:17PM  Rumors About Ackman Investment Cause Spike in ADP Shares Investopedia
03:05PM  It's Time for Investors to Get Over the Biggest Misconception About Valeant Pharmaceuticals Motley Fool
07:30AM  EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery GlobeNewswire
Jul-31-17 07:15PM  3 Value Stocks for Daring Investors Motley Fool
03:24PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is on Breakdown Watch InvestorPlace
Jul-29-17 08:08AM  Ignore the Obamacare fight in Congress and buy these 5 health-care stocks MarketWatch
Jul-28-17 12:27PM  Valeant: 3 Reasons to Buy?
Jul-27-17 07:00AM  Valeant Announces U.S. Launch of SILIQ (brodalumab) Injection CNW Group
01:00AM  Pharming Reports on Financial Results for the First Half of 2017 PR Newswire
Jul-26-17 09:30AM  Facebook, Valeant Pharmaceuticals and Advanced Micro Devices highlighted as Zacks Bull and Bear of the Day Zacks
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorAug 21Buy14.3310,000143,29682,379Aug 22 04:39 PM
DE SCHUTTER RICHARD UDirectorMay 11Buy13.9020,000278,00070,572May 15 05:19 PM
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM